NextGen’s patented product candidates hold the potential to treat cancer in a way that is effective and safe for the patient. An exciting acquisition pipeline, including in oncology therapeutics, cancer vaccines and anti-bacterial drugs, ensures that the Company is constantly positioned as a leader in the forefront of developments in treating cancer and infectious disease.
New product candidates being evaluated for potential acquisition include a number of biological products which enable the destruction of a broad range of solid tumors, including colorectal and ovarian cancers. The Company is also evaluating the potential of a protein drug which has shown potency in preventing bacterial infection. This product has a novel mechanism of action and could potentially revolutionarise the prevention of hospital acquired infections, such as MRSA or C.difficile.
The Company's objectives are to expedite the drug development process, bringing enhanced benefits to patients, while maximizing shareholder value through the following actions:
1. Further expand search, evaluation and acquisition activity to identify candidates,
2. Expand the pipeline infrastructure, including set up of contractual relationships with 9 universities.
3. Commercialize the candidates and proprietary Intellectual Property belonging to NextGen, through strategic collaborations including partnerships and licensing deals.
4. Expand the organization, including the Scientific Advisory Board.
5. In-license and file patent applications for new candidates.
6. Significantly add value to pipeline technology by outsourcing development activities to world-class organizations, at low cost
7. Leveraging available grant funding support to expedite development of and adding value to the pipeline
8. Sell off/license-out and partner for development the first target successfully by 2009.
NextGen is and will be developing the new generation of cancer treatments that are based on targeted therapy, as opposed to the current treatments, such as surgery, chemotherapy and radiation, which are all hampered with significant side effects.
We base our R&D on the most recent bioscience insight and discoveries that yet have to be applied to drug development. We intend to develop new efficacious drugs to cure cancer – without the side effects that current treatments hold. Further objectives include:
1. In-license Phase II cancer targets during 2009.
2. Develop and execute licensing agreements for the pipeline projects, including the Prostaganin and Tetanolic acid opportunities.
3. Monthly updates on collaboration deals with Big Pharma and Biotech companies
BACK TO TOP |
